POSTED ON: 30 May, 2019


The 6th edition of the International HBV Cure Workshop 2019, which will take place on 6 November 2019 in Toronto, Canada. Since 2014, the HBV Cure Workshop is a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. This meeting will bring together the world’s leading basic, translational and clinical experts to share and discuss the latest research outcomes and challenges.


Details can be found here.

Melbourne in-vivo models workshop

POSTED ON: 29 Mar, 2019

ICE-HBV in-vivo models project group is holding a workshop immediately before the International HBV Meeting. If you wish to attend, you can register here.

The objectives are:
1. Evaluation of current available models and their respective usage in various basic studies and drug assessment. Each presenter to perform a SWAT/comparative analysis of the models they present.

2. Discussion on features needed for an ideal model for assessing agent(s) with curative potential

3. Gap analysis and roadmap for developing models amenable for HBV infection and disease development. The roadmap will be published as review article/opinion piece.

The full programme can be found below and printed here.

ICE-HBV welcome and introductions T. Jake Liang 8:30-8:40
What we learned about HBV pathogenesis and immune intervention in chimpanzees, woodchucks and immunocompetent transgenic mice Luca G. Guidotti 8-40-9:15
Comparison of the Adeno-HBV, the AAV-HBV and the HBVtg mouse models Ulla Protzer 9:15-9:50
Hydrodynamic injection mouse model Pei-Jer Chen 10:05-10:25
Mouse models based on stem cell derived hepatocytes/FAH Alexander Ploss 10:25-10:45
Human liver chimeric mice and their application for drug assessment Maura Dandri 10:45-11:20
Liver and immune system humanized mouse models to study pathophysiology and therapeutics. Hélène Strick Marchand


11:20 – 11:55
Lunch Break
Mouse with humanized NTCP Wenhui Li 13:00-13:20
Towards a mouse model susceptible to HBV infection – overcoming the barrier to cccDNA formation. Jianming Hu 13:20-13:35
Macaque with human NTCP for HBV infection Ben Burwitz 13:35-13:55
Industry perspective in most wanted features for HBV animal models Scott Balsitis 13:55-14:30
Panel Discussion (facilitation by T. Jake Liang) All speakers 14:30-15:10
Closing Hélène Strick Marchand & Wenhui Li 15h10-15h30

International HBV Meeting

POSTED ON: 04 Jan, 2019

The International HBV Meeting is coming to Melbourne, the home-base of ICE-HBV. We will take this opportunity to co-organize a public forum, stay tuned!

EASL & ICE-HBV Research Think Tank – Hepatitis B Cure

POSTED ON: 28 Nov, 2018
HBV cure: the main gaps to overcome 10 April 2019 08:00 – 09:30
Linking clinical endpoint of cure to novel biomarkers
Anna LOK
10 April 2019 08:00 – 08:30
Current approaches to accelerate cure? What did we learn from recent studies?
Thomas BERG
10 April 2019 08:30 – 08:45
Effect of HBV on infected hepatocytes: how does it impact cure ? Is cure possible?
Jane McKeating
10 April 2019 08:45 – 09:00
Discussion: Is HBV cure possible and how is it defined? Where are the obstacles?
Fabien ZOULIM 
Co-Speaker: Thomas BERG, Markus Cornberg, Anna LOK, Jane McKeating, Peter Revill
10 April 2019 09:00 – 09:30
Coffee break 10 April 2019 09:30 – 10:00
Discussion – hot topics on HBV cure 10 April 2019 10:00 – 11:00
How to impact cccDNA kinetics by new treatments ? Do we need cccDNA quantification or epigenetic studies?
Barbara Testoni
10 April 2019 10:00 – 10:15
How to overcome the defects in innate and adaptive immunity to cure HBV infection ? What are the technical requirements?
Mala Maini
10 April 2019 10:15 – 10:30
Discussion: What are the best concepts to cure HBV? What are the technical requirements? How should we do the studies?
Fabien ZOULIM 
Co-Speaker: Thomas BERG, Markus Cornberg, Anna LOK, Mala Maini, Peter Revill, Barbara Testoni
10 April 2019 10:30 – 11:00

Register to EASL here.

EASL-AASLD HBV Cure Endpoints Workshop

POSTED ON: 06 Nov, 2018

The purpose of this workshop is to bring together the academic, regulatory and pharmaceutical (diagnostic and therapeutic) communities to discuss therapeutic endpoints, trial designs, appropriate patient populations and safety concerns with regards to novel therapeutic approaches aimed to achieve HBV cure. This meeting will bring all the stakeholders together to discuss definitions of HBV cure, likelihood of HBV cure with currently approved therapies, preclinical and clinical data on novel antiviral and immune modulatory therapies, appropriate designs and endpoints for trials to evaluate therapies aimed at HBV and HDV cure, and strategies to efficiently and safely evaluate combination therapies. These discussions will provide guidance regarding potential pathways leading to regulatory approval of therapies that will result in high rates of HBV cure in individuals with chronic hepatitis B and chronic hepatitis D.